Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status

Volume: 29, Issue: 3, Pages: 1123 - 1134
Published: Jan 1, 2018
Abstract
In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment.The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib...
Paper Details
Title
Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status
Published Date
Jan 1, 2018
Volume
29
Issue
3
Pages
1123 - 1134
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.